Libo Pharma (7888) Stock Overview
A clinical-stage biopharmaceutical company, engage in novel therapeutics development in the field of oncology and hematology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
7888 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Libo Pharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$29.90 |
| 52 Week High | NT$69.00 |
| 52 Week Low | NT$27.50 |
| Beta | 0 |
| 1 Month Change | -1.64% |
| 3 Month Change | -16.94% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -36.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7888 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0% | 20.0% | 2.2% |
| 1Y | n/a | 156.1% | 85.1% |
Return vs Industry: Insufficient data to determine how 7888 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 7888 performed against the TW Market.
Price Volatility
| 7888 volatility | |
|---|---|
| 7888 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in TW Market | 11.3% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 7888 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 7888's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 31 | Henry Chao | libopharma.com |
Libo Pharma Corp., a clinical-stage biopharmaceutical company, engage in novel therapeutics development in the field of oncology and hematology. The company offers LIB-101, an interleukin-12 (IL-12) cytokine immunotherapy for innate immunity, adaptive immunity, and hematopoiesis. Libo Pharma Corp. was founded in 2017 and is based in Taipei, Taiwan.
Libo Pharma Corp. Fundamentals Summary
| 7888 fundamental statistics | |
|---|---|
| Market cap | NT$2.29b |
| Earnings (TTM) | -NT$363.10m |
| Revenue (TTM) | n/a |
Is 7888 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7888 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$363.10m |
| Earnings | -NT$363.10m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.83 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7888 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 14:31 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Libo Pharma Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.